China's Leading Vaccine Developer, Sinovac, Aims To Channel Expanding Earnings Into Acquisitions
This article was originally published in PharmAsia News
Executive Summary
BEIJING - While reporting a steep rise in profits for the second quarter of this year, the leadership of Chinese vaccine developer Sinovac Biotech said the cash-rich outfit is screening potential acquisition candidates across China